Skip to main content
. 2014 Sep;58(9):5613–5616. doi: 10.1128/AAC.02973-14

TABLE 1.

In vitro antifungal susceptibility profile of mycelial and yeast forms of 23 clinical strains of H. capsulatum against 8 antifungal drugs

H. capsulatum form Parameter(μg/ml) Data for antibiotica:
AMB ITC VRC POS ISA CASb FLU 5-FC
Mycelial GM 0.11 0.043 0.102 0.05 0.055 0.097 7.05 64
MIC50/MEC50 0.125 0.03 0.125 0.06 0.06 0.125 8 32
MIC90/MEC90 0.25 0.125 0.25 0.125 0.25 0.25 16 >64
Range 0.03 to 0.25 <0.03 to 0.125 <0.03 to 0.25 0.015 to 0.125 0.015 to 0.25 0.015 to 0.5 2 to 32 8 to >64
Yeast GM 0.13 0.051 0.17 0.085 0.04 0.17 4.56 48.2
MIC50 0.125 0.06 0.25 0.06 0.06 0.25 4 16
MIC90 0.25 0.125 0.5 0.25 0.125 0.5 8 64
Range 0.03 to 0.5 0.03 to 0.25 0.03 to 0.5 0.03 to 0.5 0.015 to 0.125 0.03 to 1 2 to 8 8 to 64
Essential agreement (%)c 100 100 100 87 100 96 100 100
a

AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; ISA, isavuconazole; CAS, caspofungin; FLU, fluconazole; 5-FC, flucytosine.

b

For caspofungin, the minimal effective concentration (MEC) was read for testing the mycelial form.

c

MIC discrepancies of more than two dilutions were used to calculate the essential agreement.